General Information of DFM (ID: F19738)
Name	Selegiline 1.25 mg tablet
Company	Valeant Pharmaceuticals
Active Pharmaceutical Ingredient (API)	Selegiline		API Info click to show the detail info of this API
	Parkinsonism		ICD-11: 8A00	Approved
Drug Inactive Ingredient (DIGs)
	DIG ID	DIG Info	DIG Name	DIG Functional Class
	E0BI3X	DIG Info	Aspartame	Flavoring agent
	E09QIG	DIG Info	Citric acid monohydrate	Acidulant ...
	E0M0IE	DIG Info	Ferric hydroxide oxide yellow	Colorant
	E06WYP	DIG Info	Glycerin	Antimicrobial preservative ...
	E0Q6DQ	DIG Info	Mannitol	Diluent ...

Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM
Hydrolase (HDase)
DBT Name: Matrix metalloproteinase-1 (MMP1)				Click to Show/Hide
Detailed Information	DBT Info click to show the detail info of this DBT
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
Interacting DIG	Aspartame
Biological Activity	IC50 = 20000 nM (estimated based on the structural similarity with CHEMBL62186 )					[1]
Structural Similarity	Tanimoto coefficient = 0.916666667
Tested Species	Homo sapiens (Human)
UniProt ID	MMP1_HUMAN
Transmembrane channel/porin (TC/P)
DBT Name: Glycine receptor alpha-1 (GLRA1)				Click to Show/Hide
Detailed Information	DBT Info click to show the detail info of this DBT
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
Interacting DIG	Mannitol
Biological Activity	EC50 = 12589.25 nM (estimated based on the structural similarity with CHEMBL604608 )					[2]
Structural Similarity	Tanimoto coefficient = 0.804878049
Tested Species	Homo sapiens (Human)
UniProt ID	GLRA1_HUMAN
Nuclear receptor (NR)
DBT Name: Pregnane X receptor (NR1I2)				Click to Show/Hide
Detailed Information	DBT Info click to show the detail info of this DBT
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
Interacting DIG	Aspartame
Biological Activity	Ki = 13 uM (tested by experiment)					[3]
Tested Species	Homo sapiens (Human)
UniProt ID	NR1I2_HUMAN

References
1	Inhibition of Matrix Metalloproteinases: An examination of the S1 pocket. Bioorg Med Chem Lett. (1997) 7:193-198.
2	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
3	The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.